Press releases, Reports & Disclosures for Dubai Investments PJSC

Dubai Investments reported a profit before tax of AED 546.28 million for the first half of 2025, an increase from AED 431.68 million in the same period the previous year. For the second quarter of 2025, the profit before tax was AED 361.39 million, up from AED 309.34 million in 2024. This growth was driven by strong performances in the real estate and manufacturing sectors. The company's total assets rose to AED 22.74 billion by June 30, 2025, while equity attributable to owners decreased slightly to AED 13.89 billion. Total income for the period was AED 1.89 billion, down from AED 2.03 billion the previous year. Khalid Bin Kalban, Vice Chairman and CEO, highlighted the strength of the company's diversified portfolio and strategic focus. Looking ahead, Dubai Investments plans to accelerate growth in real estate and financial services, with ongoing projects like Asayel Avenue and Danah Bay progressing steadily. The company also plans to expand its income-generating platforms through initiatives like the Follow-On Public Offering of Al Mal Capital REIT. Dubai Investments aims to enhance shareholder value and deliver long-term sustainable returns.

Dubai Investments PJSC and its subsidiaries have released their condensed consolidated interim financial statements for the six-month period ending on June 30, 2025.

Dubai Investments has initiated construction on Asayel Avenue, a new residential cluster within the AED 2.2 billion Mirdif Hills development in Dubai. The project, developed by Dubai Investment Real Estate, will feature 193 residential apartments with modern layouts, premium finishes, and smart living technologies. Asayel Avenue aims to enhance community living with wellness amenities and landscaped spaces. Construction began in the second quarter of 2025, with completion expected by the second quarter of 2027. The project reflects Dubai Investments' commitment to quality and sustainable urban development.

Dubai Investments has reported significant year-on-year growth in its glass manufacturing sector through its subsidiary, Glass LLC, with production exceeding 14.8 million square meters in 2024. This growth is attributed to innovation, sustainability efforts, and increased demand from regional mega projects. Glass LLC includes Emirates Glass, Emirates Float Glass (EFG), and Saudi American Glass, serving various sectors like construction and energy. EFG, the only comprehensive float glass producer in the GCC, reached full production capacity, delivering over 12.6 million square meters of glass globally. It is recognized for its contribution to the UAE economy and is listed in the Abu Dhabi Department of Economic Development's Golden List. Emirates Glass also saw an 8% year-on-year increase, with significant monthly growth in December.

Dubai Investments PJSC has renewed its agreement with xCube LLC to continue as the Liquidity Provider for its shares. This move aligns with Dubai Investments' strategy to enhance shareholder value and market performance by improving the tradability of its shares. Khalid Bin Kalban, Vice Chairman and CEO of Dubai Investments, emphasized the commitment to market liquidity and long-term shareholder value, noting an increase in trading activity and investor confidence. Saad Chalabi, CEO of xCube, highlighted the effectiveness of their data-driven approach to liquidity provision. Dubai Investments, established in 1995, is a diversified investment group in the UAE, managing a broad portfolio of businesses across various sectors.

Globalpharma, a leading pharmaceutical manufacturer in the UAE, has signed four strategic Memorandums of Understanding (MoUs) during the Make it in the Emirates Forum 2025. These agreements aim to strengthen the UAE's position as a hub for pharmaceutical innovation and advanced healthcare manufacturing. The MoUs involve collaborations with PharmaPrimes Laboratories (Jordan), Nerhadou International (Egypt), Aora Health (Spain), and BioSyent Pharma Inc. (Canada), focusing on technology transfer, product licensing, supply, and local manufacturing. These partnerships align with the UAE's industrial strategy to boost domestic production, reduce import dependence, and enhance access to next-generation healthcare solutions. The agreements reflect the UAE's commitment to empowering local industry, accelerating innovation, and establishing the country as a global hub for high-quality healthcare solutions. Specific collaborations include PharmaPrimes Laboratories working on biosimilar drug capabilities in the UAE and Nerhadou International introducing a range of nutraceutical and OTC products tailored to regional health needs.